# Allarity Therapeutics Inc. (ALLR)

Source: https://www.quantisnow.com/company/ALLR
Generated: 2026-11-11T04:10:50.850Z

- Ticker: ALLR
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- SEC CIK: 0001860657
- Website: https://www.allarity.com

## About

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing oncology therapeutics using drug-specific companion diagnostics generated by its drug response predictor technology. Its drug candidates include Stenoparib, a poly-ADP-ribose polymerase inhibitor that is in Phase 2 clinical trials for ovarian cancer; Dovitinib, a pan- tyrosine kinase inhibitor for the treatment of renal cell carcinoma; IXEMPRA, a microtubule inhibitor for the treatment of metastatic breast cancer; LiPlaCis, a liposomal formulation of cisplatin, which is in Phase 2 clinical trials for metastatic breast cancer; and 2X-111, a liposomal formulation of doxorubicin that is in Phase 2 clinical trials for metastatic breast cancer and glioblastoma multiforme. The company was incorporated in 2004 and is headquartered in Cambridge, Massachusetts.

## Latest ALLR news and filings

- 2026-11-02 13:00 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-entry-into-a-6766261)
- 2026-10-30 20:10 UTC [SEC Form 424B5] [SEC Form 424B5 filed by Allarity Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b5-filed-by-allarity-therapeutics-inc-6765238)
- 2026-10-30 20:05 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Termination of a Material Definitive Agreement](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-termination-of-a-6765195)
- 2026-10-30 11:45 UTC [Allarity Therapeutics Secures First Commercial Agreement Under New CLIA Laboratory Services Strategy, Establishing Potential Path to Additional Recurring Revenue](https://www.quantisnow.com/insight/allarity-therapeutics-secures-first-commercial-agreement-under-new-clia-laboratory-6764572)
- 2026-10-09 21:12 UTC [SEC Form 4] [SEC Form 4 filed by Allarity Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-4-filed-by-allarity-therapeutics-inc-6743210)
- 2026-10-01 12:00 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6731496)
- 2026-09-30 13:00 UTC [Allarity Provides Update on Key Recent Advances Solidifying Drug Response Predictor® to Drive Stenoparib’s Clinical Development](https://www.quantisnow.com/insight/allarity-provides-update-on-key-recent-advances-solidifying-drug-response-6730191)
- 2026-09-29 12:00 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6728452)
- 2026-09-28 12:00 UTC [Allarity Therapeutics Expands Laboratory Capabilities to Include Proteomics and Cell Line Research](https://www.quantisnow.com/insight/allarity-therapeutics-expands-laboratory-capabilities-to-include-proteomics-and-cell-6727116)
- 2026-09-16 12:00 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6716956)
- 2026-09-15 12:00 UTC [Allarity Therapeutics Granted Japanese Patent for Stenoparib DRP® Companion Diagnostic, Further Strengthening Stenoparib Development](https://www.quantisnow.com/insight/allarity-therapeutics-granted-japanese-patent-for-stenoparib-drp-companion-diagnostic-6715401)
- 2026-09-14 16:14 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6714190)
- 2026-09-11 12:00 UTC [Public Offering] [Allarity Therapeutics Announces Strategic Capital Allocation for Filing of SPAC Registration Statement](https://www.quantisnow.com/insight/allarity-therapeutics-announces-strategic-capital-allocation-for-filing-of-spac-6712462)
- 2026-08-14 20:35 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-results-of-operations-6683347)
- 2026-08-14 12:02 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Allarity Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-allarity-therapeutics-inc-6681899)
- 2026-08-14 12:00 UTC [Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign](https://www.quantisnow.com/insight/allarity-therapeutics-reports-second-quarter-2026-results-and-completion-of-6681871)
- 2026-07-07 12:00 UTC [Allarity Therapeutics Announces CLIA Certification, Clearing the Path for Advancing DRP® Testing for FDA Registration](https://www.quantisnow.com/insight/allarity-therapeutics-announces-clia-certification-clearing-the-path-for-advancing-6629443)
- 2026-07-01 12:05 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-submission-of-matters-6621942)
- 2026-06-30 12:00 UTC [Allarity Therapeutics Announces the Grant of Essential U.S. Patent for Its Stenoparib DRP® Companion Diagnostic](https://www.quantisnow.com/insight/allarity-therapeutics-announces-the-grant-of-essential-us-patent-for-6619970)
- 2026-06-22 12:10 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6610109)
- 2026-06-18 12:00 UTC [Allarity Therapeutics to Present Trial-in-Progress Poster on Phase 2 Stenoparib Trial at ESMO Gynaecological Cancers Congress 2026](https://www.quantisnow.com/insight/allarity-therapeutics-to-present-trial-in-progress-poster-on-phase-2-stenoparib-6607914)
- 2026-06-02 21:10 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-leadership-update-financial-6584886)
- 2026-05-15 20:30 UTC [Allarity Therapeutics Reports First Quarter 2026 Results and Continued Stenoparib Development in Multiple Cancers](https://www.quantisnow.com/insight/allarity-therapeutics-reports-first-quarter-2026-results-and-continued-stenoparib-6557704)
- 2026-05-15 20:03 UTC [SEC Form 10-Q] [SEC Form 10-Q filed by Allarity Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-10-q-filed-by-allarity-therapeutics-inc-6557093)
- 2026-05-14 15:48 UTC [SEC Form 4] [CEO Jensen Thomas was granted 200,000 shares, increasing direct ownership by 50% to 596,734 units (SEC Form 4)](https://www.quantisnow.com/insight/ceo-jensen-thomas-was-granted-200000-shares-increasing-direct-ownership-6553087)
- 2026-05-11 19:21 UTC [SEC Form 4] [Director Hoeiland Jesper was granted 25,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/director-hoeiland-jesper-was-granted-25000-shares-sec-form-4-6544537)
- 2026-05-11 19:21 UTC [SEC Form 3] [SEC Form 3 filed by new insider Hoeiland Jesper](https://www.quantisnow.com/insight/sec-form-3-filed-by-new-insider-hoeiland-jesper-6544534)
- 2026-05-08 21:20 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-regulation-fd-disclosure-6542990)
- 2026-05-08 12:45 UTC [Conference Announcement] [Allarity Therapeutics CEO to Present at Precision Medicine Forum Europe 2026 in Stockholm](https://www.quantisnow.com/insight/allarity-therapeutics-ceo-to-present-at-precision-medicine-forum-europe-6541237)
- 2026-05-07 22:25 UTC [SEC Form 4] [Director Mclaughlin Gerald W. was granted 45,000 shares, increasing direct ownership by 180% to 70,000 units (SEC Form 4)](https://www.quantisnow.com/insight/director-mclaughlin-gerald-w-was-granted-45000-shares-increasing-direct-6540523)
- 2026-05-06 12:05 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6534203)
- 2026-05-05 12:00 UTC [Allarity Therapeutics Advances Stenoparib Toward Pivotal Development with Phase 3 Manufacturing Campaign](https://www.quantisnow.com/insight/allarity-therapeutics-advances-stenoparib-toward-pivotal-development-with-phase-3-6530867)
- 2026-04-30 21:28 UTC [SEC Form DEFA14A] [SEC Form DEFA14A filed by Allarity Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-defa14a-filed-by-allarity-therapeutics-inc-6525547)
- 2026-04-30 20:12 UTC [SEC Form DEF 14A] [SEC Form DEF 14A filed by Allarity Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-def-14a-filed-by-allarity-therapeutics-inc-6524444)
- 2026-04-30 19:38 UTC [SEC Form 4] [Amendment: Officer Graff Jeremy R. was granted 133,333 shares, increasing direct ownership by 54% to 381,644 units (SEC Form 4)](https://www.quantisnow.com/insight/amendment-officer-graff-jeremy-r-was-granted-133333-shares-increasing-6523846)
- 2026-04-30 19:37 UTC [SEC Form 4] [CFO Ervin Jeffrey S was granted 150,000 shares (SEC Form 4)](https://www.quantisnow.com/insight/cfo-ervin-jeffrey-s-was-granted-150000-shares-sec-form-6523845)
- 2026-04-28 12:03 UTC [SEC Form 8-K] [Allarity Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits](https://www.quantisnow.com/insight/allarity-therapeutics-inc-filed-sec-form-8-k-other-events-financial-6517784)
- 2026-04-27 12:00 UTC [Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office](https://www.quantisnow.com/insight/allarity-therapeutics-announces-that-the-stenoparib-drp-test-has-received-6515548)
- 2026-04-27 11:44 UTC [SEC Form 424B3] [SEC Form 424B3 filed by Allarity Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-424b3-filed-by-allarity-therapeutics-inc-6515506)
- 2026-04-27 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Allarity Therapeutics Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-allarity-therapeutics-inc-6515264)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/ALLR
- Earnings history: https://www.quantisnow.com/earnings/ALLR
- Dividend history: https://www.quantisnow.com/dividends/ALLR
- Insider transactions: https://www.quantisnow.com/insiders/ALLR
- Options chain: https://www.quantisnow.com/options/ALLR
- SEC 8-K filings only: https://www.quantisnow.com/company/ALLR/8-k
- RSS and alerts for ALLR: https://www.quantisnow.com/docs/rss-feeds.md